8-K filed Aug 5, 2026 at 16:02 ET
Mirum Pharmaceuticals reported Q2 2026 net product sales of $176.2M, a 38% YoY increase, and raised full-year guidance to $680M-$700M. However, GAAP EPS was -$1.06, a significant miss vs the -$0.75 consensus, driven by heavy R&D and SG&A spending. The volixibat NDA submission was delayed to H1 2027 after the FDA recommended a Phase 3 study, a key pipeline setback. The strong commercial performance and raised guidance are offset by the earnings miss and the volixibat delay, resulting in a mixed outlook.